Lundbeck Approaches Xeris Biopharma Over Potential Takeover, Bloomberg Reports
Danish pharmaceutical company H. Lundbeck A/S has approached Chicago-based Xeris Biopharma Holdings about a potential takeover, Bloomberg reported on September 29, citing people familiar with the matter.
Lundbeck is working with financial advisers to explore a possible acquisition, although discussions remain preliminary and may not result in a formal transaction. Neither company had immediately confirmed a deal, meaning investors should distinguish the reported interest from a signed acquisition agreement.
The development puts Xeris, a commercial-stage specialty pharmaceutical company, at the center of potential healthcare-sector M&A activity. Xeris shares have already gained substantially during 2026, supported in part by growth in its commercial portfolio and expectations surrounding its pipeline.
For investors, the key question is not simply whether Lundbeck wants to acquire Xeris, but why the Danish drugmaker may see strategic value in a company focused on endocrine and rare-disease therapies.
What Happened Between Lundbeck and Xeris?
According to Bloomberg's report, Lundbeck has expressed interest in acquiring Xeris and is working with advisers to assess a potential takeover.
The discussions are at an early stage. There is currently no confirmed transaction price, no announced acquisition agreement and no guarantee that negotiations will lead to a formal bid.
That distinction is important for shareholders. In pharmaceutical M&A, preliminary approaches can evolve into formal offers, be renegotiated or disappear entirely.
Reuters reported that Xeris and Lundbeck had not immediately responded to requests for comment following the Bloomberg report.
Why Xeris Could Be Attractive to Lundbeck
Xeris operates in areas that are somewhat different from Lundbeck's traditional focus.
Xeris develops and commercializes therapies primarily around endocrine disorders and rare neuromuscular conditions. Its current commercial portfolio includes Recorlev, Gvoke and Keveyis.
Recorlev is used to treat endogenous Cushing's syndrome, Gvoke is a ready-to-use glucagon treatment for severe hypoglycemia, and Keveyis is used for primary periodic paralysis.
This gives Lundbeck an opportunity to broaden its portfolio beyond its established neurological and psychiatric franchises.
Lundbeck's major therapeutic areas include psychiatric and neurological disorders, with products such as Rexulti and Vyepti playing important roles in its commercial business.
A potential Xeris acquisition would therefore represent more than a simple geographic expansion. It could give Lundbeck exposure to additional specialty-care markets and commercial products.
Xeris Has Been Building a Larger Commercial Business
Xeris' recent financial performance helps explain why the company could attract interest from a larger pharmaceutical group.
In August, Xeris reported second-quarter 2026 revenue of more than $92 million, while net product revenue exceeded $91 million and increased 34% year over year. Recorlev revenue rose 81% year over year to approximately $57 million. The company also tightened its full-year 2026 revenue guidance to $385 million to $390 million.
The company reported adjusted EBITDA of $34.4 million for the first six months of 2026, an improvement of $17.5 million from the same period a year earlier.
For a potential acquirer, these numbers are relevant because Xeris is not solely a development-stage biotech dependent on one future drug approval. It already has commercial products generating revenue.
That can make the acquisition case easier to evaluate than a transaction based almost entirely on unproven clinical candidates.
XP-8121 Adds Another Layer to the Deal
Xeris also has a potentially significant pipeline asset in XP-8121, an investigational once-weekly subcutaneous levothyroxine treatment for hypothyroidism.
The company said in September that initiation of a Phase 3 registrational study was on track by the end of 2026, with topline results expected in late 2028. Xeris has estimated peak net revenue potential for the product at $1 billion to $3 billion, although that is a company projection rather than guaranteed future revenue.
The distinction matters for investors.
A commercial pharmaceutical product generates observable sales today, while a Phase 3 candidate still carries clinical, regulatory and commercial risks. If XP-8121 ultimately succeeds, it could materially expand Xeris' addressable market. If development or regulatory outcomes disappoint, those expectations would need to be reassessed.
Xeris' Balance Sheet Has Also Changed
Another factor worth watching is Xeris' debt position.
In June, the company announced privately negotiated exchanges involving approximately $23 million of its 8% convertible senior notes due 2028. The transaction was designed to eliminate that debt and reduce annual interest expense by approximately $2 million.
Xeris subsequently reported that no 2028 convertible notes remained outstanding after related transactions in July.
For an acquiring company, a cleaner balance sheet can simplify transaction considerations, although the overall valuation and purchase price would remain critical.
What the Potential Deal Could Mean for Xeris Stock
Xeris had a market capitalization of approximately $1.79 billion at the close before the Bloomberg report, according to Reuters. Reuters also reported that Xeris shares had risen 27.9% year to date as of the previous close.
A potential acquisition approach can increase investor attention because shareholders may begin considering the possibility of a takeover premium.
However, investors should not treat the reported approach as confirmation that a premium-priced acquisition will occur.
There is no disclosed offer price at this stage. If negotiations fail, the stock could instead return to being valued primarily on Xeris' standalone financial performance, commercial products and pipeline prospects.
That makes the distinction between deal speculation and confirmed corporate action particularly important.
What It Could Mean for Lundbeck
For Lundbeck, acquiring Xeris could provide diversification into endocrine and rare-disease markets while adding an established commercial portfolio.
The strategic rationale would need to be weighed against the price Lundbeck ultimately pays and the risks associated with integrating another pharmaceutical business.
The potential value of the transaction could also depend heavily on XP-8121. A successful Phase 3 program and eventual regulatory approval could create a substantial additional revenue opportunity, but the timeline extends several years into the future.
Lundbeck would therefore need to assess both Xeris' current earnings power and the probability-adjusted value of its pipeline.
Key Risks Investors Should Watch
The most important risk is that there may be no deal.
The reported discussions are preliminary, and no formal transaction has been announced.
Other factors include:
- The price Lundbeck might ultimately offer for Xeris
- Whether Xeris' board supports a transaction
- Potential regulatory requirements
- The commercial performance of Recorlev, Gvoke and Keveyis
- Clinical and regulatory risks surrounding XP-8121
- Lundbeck's financing and capital-allocation strategy
- The possibility that competing buyers become interested
For Xeris shareholders, the potential takeover could create an additional valuation catalyst, but the company's standalone fundamentals remain important if negotiations do not progress.
What Investors Should Watch Next
The next major signal would be whether Lundbeck moves from preliminary discussions toward a formal proposal.
Investors should watch for announcements from either company, regulatory filings, changes in ownership disclosures and any indication of an agreed valuation.
Xeris' upcoming financial results and progress on XP-8121 will also remain important because they can influence the company's standalone value regardless of the takeover discussions.
For Lundbeck investors, the key issues will be the strategic rationale, acquisition price, financing structure and expected contribution from Xeris' commercial portfolio and pipeline.
Conclusion
Lundbeck's reported approach to Xeris Biopharma introduces a potential pharmaceutical takeover at a time when Xeris is expanding its commercial revenue and advancing its XP-8121 pipeline.
The reported discussions remain preliminary, and there is no confirmed acquisition agreement or disclosed offer price. The next stage will depend on whether Lundbeck makes a formal proposal and whether Xeris is willing to engage.
For investors, the central factors to monitor are deal valuation, the future of XP-8121, Xeris' commercial growth and Lundbeck's approach to financing and integrating a potential acquisition.
Follow the blog for more updates on pharmaceutical companies, healthcare M&A, global markets and business news.
This article is for informational and educational purposes only and should not be considered investment advice